Dublin, Nov. 12, 2019 (GLOBE NEWSWIRE) -- The "Gene Therapy in Neurology" report has been added to ResearchAndMarkets.com's offering.

Gene therapy is an evolving area in healthcare that promises to revolutionize the treatment landscapes across various therapy areas.

In this report, the focus will be on neurology indications. The report provides an analysis of the overall gene therapy pipeline that is being developed for various neurology indications with an emphasis on late-stage pipeline products. In addition to pipeline analysis, the report also focuses on trends observed in clinical trials in this area, unmet needs and challenges, as well as partnership strategies adopted by pharmaceutical companies to keep up with developments in the field of gene therapies.

Recently approved gene therapies for spinal muscular atrophy have reinvigorated the potential of such therapies to transform patient care. While various methodologies can be adopted in order to deliver therapeutic benefits of gene therapy including gene augmentation, gene suppression, and gene editing, an important component of gene therapy is whether to use viral or non-viral vectors in order to deliver such therapies to the point of care.

Ongoing collaborations between different industry players and a buildup of real-world evidence establishing safety and efficacy are expected to drive the growth of gene therapies for neurology indications. Of the 38 pipeline products that are currently in development, 45% are adeno-associated virus (AAV) based delivery platforms. Other types include Lentiviral, which accounts for 13%.

A majority of the current pipeline products are in Phase II development and the most common neurology indications - for which gene therapies are currently being evaluated - include Parkinson's disease, pain and amyotrophic lateral sclerosis. The dominance of viral vectors is expected to continue as such platforms account for the bulk of these pipeline products, with adeno-associated virus being the most common among the viral vectors.

In terms of completed, ongoing and planned clinical trials, academic institutes account for 21% of these trials, despite industry sponsors being most dominant. A deeper analysis of these clinical trials also suggest that across most indications, the average trial duration for a viral based product is longer compared to a non-viral based product such as oligonucleotides or plasmid DNA.

There are also challenges associated with the development of gene therapies, most prominent being their high price points. Key opinion leaders (KOLs) interviewed highlighted the need to create sustainable funding solutions so that such therapies become accessible to patients everywhere irrespective of where patients are located. In terms of unmet needs, KOLs highlighted the need for a favorable route of administration that is both sustainable in terms of usage of healthcare resources and favorable from a patient perspective.

While development of gene therapies are expected to pick up pace, the next wave of such therapies are expected to be ones that target diseases that are more frequent. While monogenic rare diseases are the obvious first-to-go choice for which gene therapies can be developed, targeting more frequent diseases will need a holistic approach in order to address a wider mechanism of action. If gene therapies for frequent diseases do become available, then that will result in a more pronounced effect on healthcare not only in terms of providing better treatment options for patients but also test the ability of healthcare organizations to adapt with high price points of these therapies.

Scope

Reasons to Buy

Key Topics Covered

1 Preface

2 Executive Summary2.1 Key Findings2.2 KOL Insights on Competitive Landscape for Gene Therapy for Neurology Indications

3 Overview - Gene Therapy in Neurology3.1 Objectives of Gene Therapy 3.2 Gene Therapy Versus Conventional Therapies3.3 Optimization of Gene Expression3.4 Gene Transfer Methods and Vectors Used for Gene Therapy3.5 Classifications of Gene Therapy3.6 Sources

4 Gene Therapy in the 8MM4.1 Global Regulatory Agencies' Definitions of Gene Therapy4.2 Gene Therapy in the US 4.3 Gene Therapy in the EU4.4 Gene Therapy in Japan4.5 Gene Therapy in China4.6 Currently Marketed Gene Therapies in Neurology4.7 Sources

5 Pipeline Assessment in the 8MM 5.1 Pipeline Overview 5.2 Pipeline Products - Phase III5.3 Pipeline Products - Phase II5.4 Orchard Therapeutics' OTL-200 5.5 Biogen's Tofersen Sodium5.6 Roche's RG-5.7 Sylentis' Tivanisiran5.8 ViroMed's Donaperminogene Seltoplasmid5.9 Sources

6 Clinical Trials Mapping and Design6.1 Clinical Trial Mapping for all Pipeline Products by Phase, by Sponsor, and by Location6.2 Clinical Trial Mapping for all Pipeline Products by Status and by Indication6.3 Clinical Trial Mapping by Phase and Indication for Phase III Therapies6.4 Clinical Trial Mapping by Phase for Phase II Therapies6.5 Clinical Trial Duration by Indication for Phase III Therapies (By Types of Molecules)6.6 Clinical Trial Duration by Indication for Phase II Therapies (By Types of Molecules)6.7 Ongoing Clinical Development of Phase III Gene Therapies

7 Unmet Needs, Barriers, and Key Company Strategies 7.1 Unmet Needs Within Gene Therapy for CNS Indications7.2 Challenges and Other Factors to Consider During Different Stages of Product Development7.3 Key Company Strategies: Acquisitions7.4 Key Company Strategies: Strategic Partnerships7.5 Sources

8 Payer Perspective on Gene Therapies in Neurology8.1 Current Neurology Space8.2 Challenges Associated with Reimbursement of Novel Gene Therapies8.3 Cost of Gene Therapies8.4 Strategies to Tackle the Cost of Gene Therapies8.5 Innovative Reimbursement Models and Clinical Comparators

9 Market Outlook9.1 Phase III Gene Therapy Pipeline for Neurology9.2 Key Launch Dates for Phase III Gene Therapy Pipeline Products

Companies Mentioned

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/7amvqe

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Visit link:

Gene Therapy in Neurology: 2019 Overview & Forecast Report - Yahoo Finance